{
    "clinical_study": {
        "@rank": "141306", 
        "acronym": "APEx", 
        "arm_group": [
            {
                "arm_group_label": "Aerobic Exercise Group", 
                "arm_group_type": "Experimental", 
                "description": "Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks"
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Other", 
                "description": "Standard of Care exercise recommendations"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn about the possible benefits of aerobic exercise in\n      controlling or reducing the amount of amyloid present in the brain, reducing changes in\n      brain structure that may lead to Alzheimer's Disease (AD), and increasing cognitive ability\n      in individuals that have amyloid deposits and are at risk to develop AD."
        }, 
        "brief_title": "Alzheimer's Prevention Through Exercise", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical Dementia Rating 0 (nondemented)\n\n          -  Age 65 or older\n\n          -  Florbetapir PET evidence of cerebral amyloidosis\n\n          -  Sedentary or underactive by the Telephone Assessment of Physical Activity\n\n          -  Stable doses of medications for 30 days.\n\n          -  Clinician judgment regarding subject's health status and likelihood  to successfully\n             complete the 1-year exercise intervention\n\n        Exclusion Criteria:\n\n          -  Clinically significant major psychiatric disorder (e.g., Major Depressive Disorder)\n             according to standard criteria or significant psychiatric symptoms that could impair\n             the completion of the study\n\n          -  Clinically-significant systemic illness that may affect safety or completion of the\n             study\n\n          -  History of clinically-evident stroke\n\n          -  Clinically-significant infection within the last 30 days\n\n          -  Active cardiac condition (e.g. angina, myocardial infarction, atrial fibrillation) or\n             pulmonary condition in the past 2 years that, in the investigator's opinion, could\n             pose a safety risk to the participant\u2014unless cleared for exercise by the\n             participant's primary care physician or cardiologist.\n\n          -  Uncontrolled hypertension within the last 6 months\n\n          -  History of cancer in the last 5 years (except non-metastatic basal or squamous cell\n             carcinoma)\n\n          -  History of drug or alcohol abuse as defined by DSM-IV criteria within the last 2\n             years\n\n          -  Insulin-dependent diabetes mellitus\n\n          -  Significant pain or musculoskeletal disorder prohibiting participation in an exercise\n             program\n\n          -  Unwillingness to undergo or contraindication to brain MRI scan.\n\n          -  History within the last 5 years of primary or recurrent malignant disease with the\n             exception of resected localized cutaneous squamous cell carcinoma, basal cell\n             carcinoma, cervical carcinoma, or prostate cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000583", 
            "org_study_id": "13376", 
            "secondary_id": "R01AG043962-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aerobic Exercise Group", 
                "description": "Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks", 
                "intervention_name": "Aerobic Exercise", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other", 
                "other_name": "Standard of Care for exercise recommendations"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alzheimer's Disease", 
            "AD", 
            "Aerobic Exercise", 
            "Exercise"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "email": "AVANSCIVER@kumc.edu", 
                "last_name": "Angela Van Sciver", 
                "phone": "913-945-5029"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Aerobic Exercise on Pathophysiology of PreClinical Alzheimer's Disease", 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Jeffrey Burns, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "amyloid burden measure will be mean change from baseline to 52 weeks in Florbetapir cortical-to-cerebellar ratio averaged across 6 regions of interest (frontal, temporal, parietal, anterior cingulate, posterior cingulate, and precuneus)", 
            "measure": "Change in amyloid burden", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Amount of reduction in structural brain changes in preclinical AD", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 52 weeks"
            }, 
            {
                "description": "cognitive ability to be measured using confirmatory factor analysis (CFA). CFA aggregates scores from across multiple subtests.", 
                "measure": "Change in cognitive function", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Week 52"
            }
        ], 
        "source": "University of Kansas", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Aging (NIA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}